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INTRODUCTION
The MAPK cascade (the Ras/Raf/MEK/ERK pathway) is a receptor tyrosine kinase-mediated signaling pathway that regulates cell proliferation, cell cycle progression, and cell migration (1). The frequent constitutive activation of RAS and RAF proteins has been well-established in human malignancies (2) . Mutations in the genes encoding members of the RAF protein family have been documented in 20% of cancers and 66% of melanomas (2) (3) (4) (5) (6) . This pathway has been targeted at various loci and inhibitors of B-RAF, MEK and ERK have been developed (7) . A number of MEK inhibitors such as trametinib and RO4987655 have shown activity in B-RAF and N-RAS mutant metastatic melanoma (8, 9) . In these studies, currently utilised biomarkers including B-RAF and NRAS mutations but those are not completely predictive, and responses are observed in patients not harboring these mutations (10) .
We have previously shown that plasma metabolite markers of PI3K inhibition identified in mouse models were confirmed in a Phase I clinical trial of pictilisib (GDC-0941). The changes observed are consistent with the insulin resistance phenotype developing upon treatment with PI3K inhibitors (11) .
In the present study, we evaluated whether circulating metabolites also represent attractive biomarkers to assess the sensitivity and response to MEK inhibitors. We implemented an exploratory screen for plasma metabolites exhibiting changes associated with MAPK modulation using a validated quantitative liquid chromatography-tandem mass spectrometry-based metabolomic analysis (Biocrates Absolute IDQ ®p180 kit). We first compared plasma samples from female athymic mice bearing xenografts of B-RAF mutant WM266.4 and A375 human melanoma with their non-tumor bearing age-matched littermates. We next evaluated the effect of a single dose of RO4987655 on the plasma metabolite concentrations in treated animals compared with vehicle controls. We identified a metabolomics signature consistent with MAPK activation and reversed by treatment with the MEK inhibitor. We then evaluated this signature in U87MG glioma xenografts which are driven by loss of PTEN (and thus an activated PI3 kinase pathway) following treatment with the MEK inhibitor RO4987655. We tested the hypothesis that the levels of these plasma metabolites may reflect the degree of MAPK pathway activation (e.g via B-RAF mutation); and that these novel biomarkers may be predictive of clinical outcome in addition to having pharmacodynamic utility following MEK inhibitor therapy. We tested our preclinical metabolomic signature in 35 evaluable patients with relapsed, metastatic melanoma treated with RO4987655, at the maximal tolerated dose in a non-randomized open-label Phase I clinical trial (12) . We examined the effect of treatment on metabolite concentrations and the relationship between pre-treatment baseline levels of the metabolite biomarker candidates and objective response determined by RECIST criteria (12) in 35 patients. Time-of-day variation can impact significantly the plasma metabolome (13, 14) . To assess the potential confounding impact of this factor on the candidate biomarkers, we studied the degree of variation of these metabolites in 35 subjects with advanced melanoma and in 12 healthy male volunteers over 24h.
We show that the metabolomics signature identified in the preclinical setting in the sensitive melanoma xenografts is recapitulated in patients and that baseline levels of 7 candidate biomarkers are prognostic of clinical response. 
MATERIALS & METHODS
In the exploratory preclinical screening studies, we compared plasma from female athymic mice 6-8 weeks of age inoculated subcutaneously with human WM266.4 or A375 (B-RAF mutant) melanoma cells with samples from their age-matched non-tumor bearing controls. Next, tumor-bearing and non tumor-bearing animals were randomized to receive the maximum tolerated dose of RO4987655 (6mg/kg) or cremaphor/methanol/water (1/1/3) vehicle. RO4987655 was provided by Chugai. We selected plasma metabolites that were different in tumor bearing mice compared with non-tumor bearing controls and changes that were reversed by addition of a single dose of the MEK inhibitor in both xenograft models.
A metabolic signature identified from these studies was then tested in the PTEN (-/-) null U87MG human glioblastoma xenograft. The signature was also tested in the Phase I clinical study with RO4987655 in patients with advanced metastatic melanoma. Finally we applied the MEK signature to patients with advanced solid tumors in a Phase I clinical study of the PI3K inhibitor pictilisib (clinicaltrials.gov identifier: NCT00876122) (15, 16) .
Preclinical human tumor xenograft studies
All animal experiments were conducted in accordance with local and UK National Cancer Research Institute guidelines (17) profiling. Polymorphic STR loci were amplified using a PCR primer set. The PCR product (each locus was labelled with a different fluorophore) was analysed simultaneously with size standards by using an automated fluorescent detection technique. The number of repeats at 7-10 different loci defines the STR profile and was cross-referenced with online databases to confirm authenticity. All cell lines showed 100% match and were mycoplasma negative. In pharmacodynamics, metabolomics and therapy studies, blood samples were collected (using sodium heparin as anticoagulant) and tumors were snap frozen. The blood samples were centrifuged at 13000 rpm for 2 min and the plasma transferred onto dry ice; the entire process from collection to storage in dry ice and analysis of pictilisib responses have been described previously (15, 16) .
Plasma metabolomics analysis
We carried out targeted, quantitative metabolomic analysis by electrospray ionization tandem MS using the 
Data analysis
The analytical process to derive metabolite concentrations was performed using MassLynx™ (Waters corporation Manchester UK) and the MetIDQ software package (Biocrates Life Sciences, Insbruck, Austria.)
Multivariate analysis was performed using SIMCA v.14.1 software (MKS Umetrics AB, Sweden); to determine metabolite features that were differentially expressed between defined groups of mice: (1) differences were identified using OPLS-DA (18) with a threshold of variable importance in the projection (VIP) value >0.5 and cross validation by permutation analysis carried out. To pass the exploratory preclinical screen and establish the signature, a metabolite was required to be affected consistently across tumor-bearing mice versus controls and to show reverse changes in xenograft-bearing mice treated with a single dose of the MEK inhibitor. For the relevant plasma metabolites at each time point the changes relative to control concentration (pre-treatment or vehicle) were used to generate heat maps. We tested the metabolomics signature identified in melanoma mice with an additional cohort bearing PTEN null U87MG human glioblastoma xenografts following treatment with a single dose of the MEK inhibitor.
In the clinical studies with the MEK inhibitor and the PI3K inhibitor, we focused on the metabolites that had been identified in the pre-clinical studies. Changes relative to pre-treatment baseline levels were calculated for each patient across all time points for each metabolite. In the study with the MEK inhibitor, the separation between the response categories of disease progression and objective RECIST response (Response Evaluation Criteria in Solid tumors) was assessed using the receiver operator characteristic (ROC) curve. The statistical significance of the differences were determined using Mann-Whitney, Kruskall- 
RESULTS

Preclinical models
RO4987655 inhibits ERK phosphorylation and tumor growth in human melanoma xenografts
Following a single dose of 6mg/kg RO4987655 to female athymic mice bearing s.c. human B-RAF mutant melanoma xenografts WM266.4 or A375 a complete inhibition of ERK phosphorylation was observed in tumors at 2,6 and 8h post treatment in both models (Fig. 1A and B) . This target modulation resulted in significant tumor growth inhibition following daily treatment with RO4987655 at 6mg/kg with T/C of 16% and 3.5% respectively (Fig. 1C) .This schedule was well tolerated with no body weight loss.
The metabolomics workflow is summarized in Fig. 2A 
Identification of the metabolomic signature
We compared plasma samples from mice bearing WM266.4 and A375 melanomas with their non-tumor bearing age-matched littermates. Orthogonal partial least square-discriminant analysis (OPLS-DA) of the metabolic profile revealed 11 metabolites increased in these MAPK-driven tumors and decreased following RO4987655 treatment plus 10 metabolites decreased in the plasma of tumor bearing mice and increased following treatment (summarized in Fig. 2B and Fig. 2C ). Hence, a total of 21 metabolites including propionylcarnitine, arginine, asparagine, isoleucine, leucine, phenylalanine, tryptophan, tyrosine, valine, (Fig. 2D) . Overall, propionylcarnitine and the aminoacids were decreased in the plasma of tumor bearing animals compared with controls and increased by treatment. In contrast, lipids were increased in plasma of tumor bearing mice and decreased with treatment (Fig. 2D) . In tumor bearing mice, the metabolic effects were most pronounced at 4 and 8h and were different from those observed in non-tumor bearing mice (Fig 2D) . In the PTEN (-/-) null human glioblastoma xenograft (U87MG), which is not MAPK-dependent, a single dose of the MEK inhibitor had different effects on the plasma metabolites identified in melanoma models ( (Fig. 3A) . The most significant effects were observed on propionylcarnitine, and aminoacids that showed an increase at all time points. The sphingomyelins and one phosphatidylcholine (PC aa C38:6) showed an overall decrease at 24h but this was not statistically significant (Table 1 , Fig. 3B PD-PR-SD column). Additionally, the metabolic alterations were significantly different between patients with disease progression and those who achieved an objective response (Fig. 3B , PD and PR columns). Overall, progressors showed a significant increase in amino acids relative to pre-dose levels while responders showed no significant increase in these amino acids up to Cycle 2, 24h. In addition, a significant decrease in 7 phospholipids was observed from cycle 2 which was not observed in patients who progressed. The metabolite changes observed in responsive patients were consistent with the effects observed in mice bearing the sensitive WM266.4 and A375 melanoma xenografts and the effects in non-responsive patients were in line with the effects in non-tumour bearing mice or the U87MG xenograft model (Fig. 2C, Fig. 3B , Table 2 ). In addition, the effect of the PI3K inhibitor pictilisib on the MEK signature also showed an increase in the amino acids but no decrease in phospholipids which is comparable with that observed in patients with progressive disease following RO4987655 administration. The effect on amino acids following pictilisib was not observed below 80mg (suggesting that it is genuinely associated with PI3K inhibition and not disease progression) (Supplementary Figure 1) . 
Baseline levels of 7 plasma metabolites predict clinical response to RO4987655
We examined the relationship between pre-treatment baseline levels of the metabolite biomarker candidates and objective response determined by RECIST criteria (12) (Table 3 ). The plasma levels of all these lipid metabolites were higher in patients who subsequently achieved an objective response to RO4987655. (Fig.3B) . In contrast, a poor separation between the metabolic profiles of patients harbouring B-RAF-mutant and B-RAF wild-type melanomas was observed with only 3 metabolites correlating with B-RAF mutational status. The lack of a significant difference in these plasma metabolites between the two groups is summarised in Table   3 .
A heat map of an unsupervised analysis of the pre-treatment levels of selected lipids (based on preclinical signature Fig. 3C ) shows clustering of 7/8 all of patients with partial response and 11/12 patients with progressive disease (Fig. 3C) .
Collectively, these results suggest hitherto-unknown biological pathways involving the panel of metabolite biomarkers being implicated in mechanisms underlying vulnerability of melanoma cells to MEK inhibition. A summary of the levels of 4 representative metabolites throughout the course of treatment is presented in Fig. 3D .
Changes in the metabolite biomarkers following RO4987655 exceed time-of-day variations
Time-of-day variation can impact significantly on the plasma metabolome (13, 14) . To assess the potential confounding impact of this factor on the candidate biomarkers, we studied the degree of variation of these metabolites in an additional study (Supplementary Table 1 
DISCUSSION
This study provides evidence of plasma metabolites as biomarkers predictive of objective response to a molecularly targeted anti-cancer drug with good discrimination. The prior identification of biomarker candidates in molecularly-characterized preclinical tumor screens where control animals were included significantly increases confidence that these metabolites represent genuine exometabolomic changes associated with MAPK pathway modulation.
We demonstrated that basal levels of 21 metabolites including amino acids, glycerophosphocholines and sphingomyelins were differentially affected in clinical responders and progressors following treatment with RO4987655. In patients with progressive disease, we observed an increase in amino acids and no decrease in lipids. This significant increase in amino acids was also observed following treatment with the PI3K inhibitor pictilisib where no therapeutic benefit was observed in all but one patient (15, 16) . In patients responding to the MEK inhibitor, the amino acids and lipids were decreased. In addition, basal levels of 7 metabolites (glycerophosphocholines and sphingomyelins) were significantly able to predict response with higher levels in responders.In contrast to the metabolite biomarker changes, the median decrease in ERK phosphorylation in tumors was higher in patients with a B-RAF mutation than those without; but there was no evidence of a significant difference in pERK inhibition between different response outcome groups (12) .
A previous study showed that reduction of p-ERK was correlated with response to the B-RAF inhibitor vemurafenib (20) ; however, there is published evidence that this is not the case for MEK inhibitors (12) . In addition, the metabolic responses measured by FDG-PET confirmed the negative predictive value of FDG-PET for MEK inhibition (10) . In this context, it is notable that we observe an increase in branched chain amino acids in non-responders and following treatment with pictilisib which is consistent with the insulin resistant phenotype (16) . In addition, our previous studies showed a decrease in glycerophosphocholine in PI3K-activated tumors and an increase following PI3K inhibition with pictilisib (16) of these phospholipids are predictive of resistance to the MEK inhibitor is consistent with the PI3K activated metabotype. It has been shown that de novo PI3K activation is associated with resistance to MEK inhibitors (21) which is consistent with our metabolic findings. PI3K activation is also known to be induced as a result of MEK inhibition but our metabolic response to doses of drug inhibiting the MAPK pathway does not recapitulate that observed upon PI3K activation whatever the therapeutic outcome. Studies aiming at the prediction of sensitivity to MEK inhibition by gene expression profiling have also shown compensatory signaling through RAS effectors other than PI3K (22) . Tumors often harbor genetic abnormalities in both PI3K and MAPK pathways as observed in WM266.4 (although they are known to be driven primarily by MAPK). In addition, PI3K pathway abnormalities in the patients enrolled in the clinical study have not been determined and melanomas have a high mutational load in addition to the known PI3K and MAPK drivers (23-25). Our exometabolomic data in sensitive human tumor xenograft models and clinical responders are in agreement with cellular metabolomics studies by NMR reporting decreased glycerophosphocholine levels which were associated with lowered expression of choline-kinase α following MEK inhibition (26) . Increased levels of phosphatidylcholines ,delivered by nanoparticles, in the cellular plasma membrane is able to activate EGFR which is one of the major mechanisms of resistance to MEK inhibition suggesting effectors for these molecules upstream and downstream of MAPK (23, 27, 28) . Similarly, previous studies established that activated sphingomyelinase leads to ceramide-mediated activation of MAPK (29) . In our study, we show a decrease in sphingomyelins following MEK inhibition suggesting complex regulation of sphingomyelins on the MAPK network.
We and others have demonstrated that levels of plasma metabolites vary throughout the day (12, 13) . readily amenable to repeated sampling. In addition, the use of a mass spectrometry-based platform crucially allows for up-scaling and implementation in large studies. We emphasize, however, that this is a retrospective study with a limited sample size, and hence cannot be regarded as definitive at this time.
Further investigations in an independent cohort are needed. This is challenging given the fact that MEK inhibitors are now administered in combination in the clinical setting. Although the mechanistic links between MAPK pathway modulation and the panel of plasma metabolite biomarkers are currently poorly understood, we anticipate that our novel findings may be helpful in guiding future investigations including those of MEK inhibitor resistance.
In summary, using LC-MS metabolomics, we showed that plasma metabolite markers of MEK inhibition can be identified in mice bearing human melanoma xenografts. In patients with advanced melanoma treated with RO4987655, the pre-treatment levels of 7 candidate plasma metabolite biomarkers identified in the pre-clinical screen were statistically significantly able to retrospectively predict objective responses to RO4987655. Our current findings and those we reported previously (10) 
